SGLT2 inhibitors and GLP-1 receptor agonists are used in patients with type 2 diabetes as
glucose lowering therapies, with additional benefits of weight loss and blood pressure …

Recent large clinical trials on sodium-glucose cotransporter 2 (SGLT2) inhibitors and
glucagon-like peptide-1 (GLP-1) receptor agonists, with the aim of verifying cardiovascular …

Objective To evaluate sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-
like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes at varying …

Results Cardiovascular disease represents a large health burden in patients with diabetes.
The prevention of cardiovascular events is a major concern in the treatment of patients with …

Background The magnitude of effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i)
on specific cardiovascular and renal outcomes and whether heterogeneity is based on key …

Background Despite strong evidence of benefit, uptake of newer glucose-lowering
medications that reduce cardiovascular risk has been low. We sought to examine global …

Clinical question What are the benefits and harms of sodium-glucose cotransporter 2 (SGLT-
2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists when added to usual …

Cardiovascular outcome trials in patients with type 2 diabetes at high cardiovascular risk
have led to remarkable advances in our understanding of the effectiveness of GLP-1 …

Among persons with type 2 diabetes (t2d), the development of glucose intolerance involves
dysfunction in several organs and tissues, including the muscle, liver, pancreas, kidney …

Sodium-glucose cotransporter type 2 inhibitors (SGLT2is) and glucagon-like peptide-1
receptor agonists (GLP-1RAs) are two pharmacological classes that have proven their …